<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107807</url>
  </required_header>
  <id_info>
    <org_study_id>V87_26</org_study_id>
    <secondary_id>2011-003573-28</secondary_id>
    <nct_id>NCT02107807</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine</brief_title>
  <official_title>A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18
      through 60 years of age) and elderly (≥61 years of age) subjects with and without
      immunosuppressive conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving seroconversion*</measure>
    <time_frame>day 43</time_frame>
    <description>*seroconversion: (defined as HI ≥1:40 for subjects who were seronegative at baseline [day 1 HI titer &lt;1:10] or a minimum 4-fold increase in HI titer for subjects who were seropositive at baseline [day 1 HI titer
≥1:10]) on day 43.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratios (GMRs) as determined by HI assay</measure>
    <time_frame>day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with an HI titer ≥1:40</measure>
    <time_frame>day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited and unsolicited adverse events</measure>
    <time_frame>day 202</time_frame>
    <description>In pooled age groups 18 years of age and older subjects who are healthy or with underlying medical condition who have received aTIV or aH5N1 vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers as determined by Hemagglutination Inhibition</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers as determined by Hemagglutination Inhibition</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers as determined by Hemagglutination Inhibition</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers as determined by Single Radial Hemolysis</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers as determined by Single Radial Hemolysis</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers as determined by Single Radial Hemolysis</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio as determined by Hemagglutination Inhibition</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio as determined by Hemagglutination Inhibition</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio as determined by Single Radial Hemolysis</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio as determined by Single Radial Hemolysis</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion determined by HI</measure>
    <time_frame>Day 22</time_frame>
    <description>seroconversion is defined as HI ≥1:40 for subjects who were seronegative at baseline [day 1 HI titer &lt;1:10] or a minimum 4-fold increase in HI titer for subjects who were seropositive at baseline [day 1 HI titer ≥1:10]) on days 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion determined by SRH</measure>
    <time_frame>Day 22</time_frame>
    <description>seroconversion (defined as SRH area ≥25 mm2 for subjects who were seronegative at baseline [day 1 SRH area ≤3.997 mm2] or a significant increase [at least 50% increase] in SRH area for subjects who were seropositive at baseline [SRH area &gt;3.997 mm2]) on days 22, 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion determined by SRH</measure>
    <time_frame>Day 43</time_frame>
    <description>seroconversion is defined as SRH area ≥25 mm2 for subjects who were seronegative at baseline [day 1 SRH area ≤3.997 mm2] or a significant increase [at least 50% increase] in SRH area for subjects who were seropositive at baseline [SRH area &gt;3.997 mm2]) on days 22, 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an HI titer ≥1:40</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an HI titer ≥1:40</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with geometric mean area ≥25 mm2</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with geometric mean area ≥25 mm2</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with geometric mean area ≥25 mm2</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">539</enrollment>
  <condition>Influenza, Human</condition>
  <condition>Flu, Human</condition>
  <condition>Flu, Avian</condition>
  <condition>Influenza</condition>
  <condition>Influenza A Virus, H5N1 Subtype</condition>
  <arm_group>
    <arm_group_label>Arm 1: aH5N1 adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aH5N1 healthy and non-healthy adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: aH5N1 elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aH5N1 healthy and non-healthy elderly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: aTIV elderly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aTIV healthy and non-healthy elderly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: aTIV adult</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aTIV healthy and non-healthy adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Investigational H5N1 vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 1: aH5N1 adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Investigational H5N1 vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 2: aH5N1 elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Seasonal Influenza Vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 4: aTIV elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Seasonal Influenza Vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 3: aTIV adult</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female individuals 18 years of age and older at the time of enrollment who
             are mentally competent, willing and able to understand the nature and risks of the
             proposed study, and able to sign the consent form prior to study entry;

          -  Individuals who are able to comply with all study procedures and requirements;

          -  Healthy volunteers and volunteers specifically HIV positive, transplant recipients,
             cancer patients may be eligible;

          -  Please contact the site for additional eligibility criteria.

        Exclusion Criteria:

          -  Individuals who are not able to follow all the required study procedures for the whole
             period of the study;

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the Investigator, may interfere with the subject's ability to
             participate in the study;

          -  Please contact the site for additional eligibility criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>102, Novartis Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103, Novartis Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101, Novartis Investigational Site</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303, Novartis Investiagtional Site</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304, Novartis Investigational Site</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301, Novartis Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302, Novartis Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>082, Novartis Investigational Site</name>
      <address>
        <city>Fossacesia</city>
        <state>Chieti</state>
        <zip>66022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>081, Novartis Investigational Site</name>
      <address>
        <city>Lanciano</city>
        <state>Chieti</state>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>003, Novartis Investigational Site</name>
      <address>
        <city>Monza</city>
        <state>Milan</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>007, Novartis Investigational Site</name>
      <address>
        <city>Aviano</city>
        <state>Padova</state>
        <zip>33080</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>006, Novartis Investigational Site</name>
      <address>
        <city>San Daniele del Friuli</city>
        <state>Udine</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>005, Novartis Investigational Site</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>008, Novartis Investigational Site</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>001, Novartis Investigational Site</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>002, Novartis Investigational Site</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>004, Novartis Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001 Mar 21;19(17-19):2673-80.</citation>
    <PMID>11257408</PMID>
  </reference>
  <reference>
    <citation>Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.</citation>
    <PMID>17029131</PMID>
  </reference>
  <reference>
    <citation>Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/5f2ae0fb-53f1-48c2-aa19-9114765ba029. Capecchi, Pamela [corrected to Capecchi, Pier Leopoldo].</citation>
    <PMID>19197383</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza,</keyword>
  <keyword>H5N1</keyword>
  <keyword>aH5N1</keyword>
  <keyword>H5N1 vaccine</keyword>
  <keyword>Pandemic Influenza vaccine</keyword>
  <keyword>MF59</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Avian flu</keyword>
  <keyword>Underlying Immunosuppressive</keyword>
  <keyword>immunosuppressive conditions</keyword>
  <keyword>Pandemic vaccine</keyword>
  <keyword>Adjuvanted vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

